Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3381 - Myeloid-Derived Suppressor Cells are associated with a decrease of tumor antigen-specific Th1 immunity in Non-Small Cell Lung Cancer.

Date

11 Sep 2017

Session

Poster display session

Topics

Translational Research;  Thoracic Malignancies

Presenters

Olivier Adotevi

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

O. Adotevi1, E. Lauret Marie Joseph1, C. Laheurte1, M. Dosset1, E. Fabre-Guillevin2, P. Jacoulet3, G. Eberts3, G. Helluin1, L. Boullerot1, L. Rangan1, Y. Godet1, V. Westeel3

Author affiliations

  • 1 Thérapeutique Immuno-moléculaire Des Cancers, UMR1098, 25020 - Besançon/FR
  • 2 Medical Oncology, Dr. Elizabeth Fabre-Guillevin, 75015 - La Défense/FR
  • 3 Pneumology, CHRU Jean Minjoz, 25000 - Besançon/FR
More

Resources

Abstract 3381

Background

Myeloid Derived Suppressor cells (MDSC) are immune suppressive cells associated with poor survival in several cancers. In this study, we investigated their impact on spontaneous tumor antigen specific Th1 responses in Non-Small Cell Lung Cancer (NSCLC).

Methods

Monocytic MDSC (M-MDSC) (Lin-HL-DR-/loCD11b+CD14+CD33+) were measured in peripheral blood of 122 NSCLC patients and 34 healthy donors by flow cytometry. The presence of spontaneous anti-tumor Th1 response was measured by IFN-ɣ ELISPOT assay using mixture of peptides derived from lung cancer-associated tumor antigens such as telomerase, NY-ESO1 and Wilms Tumor-1. Patients’ samples were collected at baseline before any treatment.

Results

Higher percentage of circulating M-MDSC was found in NSCLC patients compared to healthy subjects (mean: 3.9±0.4% vs 1.5±0.4%, p 

Conclusions

Our results show that high levels of circulating M-MDSC is associated with a decrease of pre-existing antitumor T cell response. The level of M-MDSC combined with antitumor T cell responses could predict distinct clinical outcome. Thus, monitoring M-MDSC in blood could be used as relevant immune biomarker in NSCLC.

Clinical trial identification

Legal entity responsible for the study

Adotevi Olivier

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.